| scholarly article | Q13442814 |
| P2093 | author name string | Cox DA | |
| Leader JP | |||
| Milson JA | |||
| Singleton W | |||
| P2860 | cites work | MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party | Q24541570 |
| A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension | Q34446826 | ||
| Clinical pharmacological studies with doxazosin | Q34446840 | ||
| Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins | Q34446855 | ||
| Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension | Q34446862 | ||
| The veterans trial and sequelae | Q34448957 | ||
| Haemodynamics in Essential Hypertension | Q40083512 | ||
| Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application | Q40331073 | ||
| Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man | Q42116080 | ||
| A pharmacodynamic and pharmacokinetic assessment of a new alpha- adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects | Q43241370 | ||
| Pathophysiologic clinical clues in essential hypertension: a rationale for initial therapy | Q46617673 | ||
| Determination of the vasodilator UK33274 by high-performance liquid chromatography using fluorescence detection | Q70537765 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 83S-90S | |
| P577 | publication date | 1986-01-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | The antihypertensive effects of doxazosin: a clinical overview | |
| P478 | volume | 21 Suppl 1 |
| Q36495545 | Alpha 1 blockers. Safe, effective treatment for hypertension |
| Q38365267 | Alpha-1 blockers. A new generation of antihypertensive agents |
| Q37608000 | Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism |
| Q39554976 | Alterations in lipid metabolism induced by antihypertensive therapy. |
| Q67897240 | Clinical experience with doxazosin in general medical practice in New Zealand |
| Q34397966 | Concentration-effect relationships and individual responses to doxazosin in essential hypertension |
| Q35831785 | Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model |
| Q67897237 | Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension |
| Q68290032 | Doxazosin for the treatment of chronic congestive heart failure: Results of a randomized double-blind and placebo-controlled study |
| Q37012904 | Doxazosin in metabolically complicated hypertension. |
| Q39469038 | Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension |
| Q40399993 | Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia |
| Q67897247 | Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension |
| Q31145309 | Effects of doxazosin on serum lipids: A review of the clinical data and molecular basis for altered lipid metabolism |
| Q37677533 | Newer antihypertensive agents |
| Q38367793 | Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists |
| Q36552496 | Selective α1-adrenoreceptor blockers in the treatment of hypertension: Should we be using them more? |
| Q57986892 | Single-Dose and Steady-State Pharmacokinetics of Doxazosin Given in Combination with Chlorothiazide to Hypertensive Subjects |
| Q93753868 | Summary |
| Q44916174 | The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by by β-blockers |
| Q40619283 | The place of alpha blockers in the treatment of hypertension |
Search more.